Header Logo

Connection

HASHEM EL-SERAG to Barrett Esophagus

Back to Details
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Barrett Esophagus.
HASHEM EL-SERAG
Connection Strength
20.893
Barrett Esophagus
  1. Why Has Screening and Surveillance for Barrett's Esophagus Fallen Short in Stemming the Rising Incidence of Esophageal Adenocarcinoma? Am J Gastroenterol. 2023 04 01; 118(4):590-592.
    View in: PubMed
    Score: 0.597
  2. Limits of the AGA Practice Update for Barrett's Esophagus Screening: A Proposal for Electronic Health Record-Adaptable Risk Models. Clin Gastroenterol Hepatol. 2023 Jul; 21(7):1963-1964.
    View in: PubMed
    Score: 0.585
  3. Development and Validation of the Houston-BEST, a Barrett's Esophagus Risk Prediction Model Adaptable to Electronic Health Records. Clin Gastroenterol Hepatol. 2023 08; 21(9):2424-2426.e0.
    View in: PubMed
    Score: 0.582
  4. External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans. Gastrointest Endosc. 2022 06; 95(6):1113-1122.
    View in: PubMed
    Score: 0.558
  5. Current Status of Chemoprevention in Barrett's Esophagus. Gastrointest Endosc Clin N Am. 2021 Jan; 31(1):117-130.
    View in: PubMed
    Score: 0.514
  6. Prevalence of Barrett's esophagus and performance of societal?screening guidelines in an unreferred primary care population of U.S. veterans. Gastrointest Endosc. 2021 02; 93(2):409-419.e1.
    View in: PubMed
    Score: 0.501
  7. Chemoprevention of Barrett's oesophagus: a step closer with PPIs and aspirin. Nat Rev Clin Oncol. 2018 12; 15(12):728-730.
    View in: PubMed
    Score: 0.450
  8. Endoscopic ablation of low-grade dysplasia in Barrett's?esophagus: Have all the boxes been checked for?us?to move on? Gastrointest Endosc. 2017 07; 86(1):130-132.
    View in: PubMed
    Score: 0.408
  9. External Validation of the Michigan Barrett's Esophagus Prediction Tool. Clin Gastroenterol Hepatol. 2017 07; 15(7):1124-1126.
    View in: PubMed
    Score: 0.399
  10. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol. 2017 Jul; 112(7):1049-1055.
    View in: PubMed
    Score: 0.399
  11. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus. Gut. 2016 08; 65(8):1252-60.
    View in: PubMed
    Score: 0.359
  12. Prevalence of Barrett's Esophagus in Asian Countries: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1907-18.
    View in: PubMed
    Score: 0.358
  13. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study. Gastroenterology. 2015 Nov; 149(6):1392-8.
    View in: PubMed
    Score: 0.357
  14. Metabolic syndrome and the risk of Barrett's oesophagus in white males. Aliment Pharmacol Ther. 2015 Jun; 41(11):1182-9.
    View in: PubMed
    Score: 0.348
  15. Risk factors for Barrett's esophagus compared between African Americans and non-Hispanic Whites. Am J Gastroenterol. 2014 Dec; 109(12):1870-80.
    View in: PubMed
    Score: 0.341
  16. The incidence of esophageal adenocarcinoma in a national veterans cohort with Barrett's esophagus. Am J Gastroenterol. 2014 Dec; 109(12):1862-8; quiz 1861, 1869.
    View in: PubMed
    Score: 0.339
  17. Esophageal COX-2 expression is increased in Barrett's esophagus, obesity, and smoking. Dig Dis Sci. 2015 Jan; 60(1):65-73.
    View in: PubMed
    Score: 0.336
  18. Decision aids for shared decision-making in Barrett's esophagus surveillance. Clin Gastroenterol Hepatol. 2015 Jan; 13(1):91-3.
    View in: PubMed
    Score: 0.328
  19. Statin use is associated with a decreased risk of Barrett's esophagus. Gastroenterology. 2014 Aug; 147(2):314-23.
    View in: PubMed
    Score: 0.328
  20. Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagus. Clin Gastroenterol Hepatol. 2014 Nov; 12(11):1832-9.e6.
    View in: PubMed
    Score: 0.328
  21. Brief report: the length of newly diagnosed Barrett's esophagus may be decreasing. Dis Esophagus. 2015 Jul; 28(5):418-21.
    View in: PubMed
    Score: 0.326
  22. Use and yield of endoscopy in patients with uncomplicated gastroesophageal reflux disorder. JAMA Intern Med. 2014 Mar; 174(3):462-5.
    View in: PubMed
    Score: 0.324
  23. Personal and family history of cancer and the risk of Barrett's esophagus in men. Dis Esophagus. 2015 Apr; 28(3):283-90.
    View in: PubMed
    Score: 0.323
  24. A multibiomarker risk score helps predict risk for Barrett's esophagus. Clin Gastroenterol Hepatol. 2014 Aug; 12(8):1267-71.
    View in: PubMed
    Score: 0.319
  25. Barrett's esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what's next? Am J Gastroenterol. 2014 Feb; 109(2):178-82.
    View in: PubMed
    Score: 0.319
  26. Poor sleep quality and obstructive sleep apnea in patients with GERD and Barrett's esophagus. Neurogastroenterol Motil. 2014 Mar; 26(3):346-52.
    View in: PubMed
    Score: 0.319
  27. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. 2014 Aug; 63(8):1229-37.
    View in: PubMed
    Score: 0.317
  28. No significant effects of smoking or alcohol consumption on risk of Barrett's esophagus. Dig Dis Sci. 2014 Jan; 59(1):108-16.
    View in: PubMed
    Score: 0.315
  29. Dietary consumption of meat, fat, animal products and advanced glycation end-products and the risk of Barrett's oesophagus. Aliment Pharmacol Ther. 2013 Oct; 38(7):817-24.
    View in: PubMed
    Score: 0.312
  30. Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans. Am J Gastroenterol. 2013 Oct; 108(10):1576-83.
    View in: PubMed
    Score: 0.310
  31. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol. 2013 Jun; 108(6):915-22.
    View in: PubMed
    Score: 0.304
  32. Dietary intake of vegetables, folate, and antioxidants and the risk of Barrett's esophagus. Cancer Causes Control. 2013 May; 24(5):1005-14.
    View in: PubMed
    Score: 0.302
  33. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut. 2014 Feb; 63(2):220-9.
    View in: PubMed
    Score: 0.301
  34. Occupational exposure and the risk of Barrett's esophagus: a case-control study. Dig Dis Sci. 2013 Jul; 58(7):1967-75.
    View in: PubMed
    Score: 0.301
  35. Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol. 2013 Apr; 11(4):373-381.e1.
    View in: PubMed
    Score: 0.297
  36. Practice patterns of surveillance endoscopy in a Veterans Affairs database of 29,504 patients with Barrett's esophagus. Gastrointest Endosc. 2012 Oct; 76(4):743-55.
    View in: PubMed
    Score: 0.294
  37. Human papillomavirus and the risk of Barrett's esophagus. Dis Esophagus. 2013 Jul; 26(5):517-21.
    View in: PubMed
    Score: 0.291
  38. The association between Barrett's esophagus and Helicobacter pylori infection: a meta-analysis. Helicobacter. 2012 Jun; 17(3):163-75.
    View in: PubMed
    Score: 0.283
  39. Expression of androgen receptors in Barrett esophagus. J Clin Gastroenterol. 2012 Mar; 46(3):251-2.
    View in: PubMed
    Score: 0.282
  40. Routine polypectomy for colorectal polyps and ablation for Barrett's esophagus are intellectually the same. Gastroenterology. 2011 Feb; 140(2):386-8.
    View in: PubMed
    Score: 0.259
  41. Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Dig Dis Sci. 2010 Dec; 55(12):3404-7.
    View in: PubMed
    Score: 0.248
  42. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology. 2010 Jun; 138(7):2260-6.
    View in: PubMed
    Score: 0.245
  43. Surveillance in Barrett's esophagus: lessons from behavioral economics. Gastroenterology. 2009 Sep; 137(3):763-5.
    View in: PubMed
    Score: 0.236
  44. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. Am J Gastroenterol. 2009 Sep; 104(9):2161-7.
    View in: PubMed
    Score: 0.234
  45. Alcohol drinking and the risk of Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 2009 Apr; 136(4):1155-7.
    View in: PubMed
    Score: 0.229
  46. Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis. Dis Esophagus. 2009; 22(7):571-87.
    View in: PubMed
    Score: 0.228
  47. Gene expression in Barrett's esophagus: laser capture versus whole tissue. Scand J Gastroenterol. 2009; 44(7):787-95.
    View in: PubMed
    Score: 0.226
  48. The use of acid-decreasing medication in veteran patients with gastro-oesophageal reflux disorder with and without Barrett's oesophagus. Aliment Pharmacol Ther. 2008 Jun; 27(12):1293-9.
    View in: PubMed
    Score: 0.214
  49. The use of cytokeratin stain to distinguish Barrett's esophagus from contiguous tissues: a systematic review. Dig Dis Sci. 2007 May; 52(5):1345-54.
    View in: PubMed
    Score: 0.200
  50. The prevalence of suspected Barrett's esophagus in children and adolescents: a multicenter endoscopic study. Gastrointest Endosc. 2006 Nov; 64(5):671-5.
    View in: PubMed
    Score: 0.195
  51. Is genomic evaluation feasible in endoscopic studies of Barrett's esophagus? A pilot study. Gastrointest Endosc. 2006 Jul; 64(1):17-26.
    View in: PubMed
    Score: 0.190
  52. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol. 2005 Oct; 100(10):2151-6.
    View in: PubMed
    Score: 0.181
  53. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol. 2004 Oct; 99(10):1877-83.
    View in: PubMed
    Score: 0.169
  54. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy. Aliment Pharmacol Ther. 2004 Jun 15; 19(12):1255-60.
    View in: PubMed
    Score: 0.165
  55. Is the length of newly diagnosed Barrett's esophagus decreasing? The experience of a VA Health Care System. Clin Gastroenterol Hepatol. 2004 Apr; 2(4):296-300.
    View in: PubMed
    Score: 0.163
  56. Using Natural Language Processing to Automatically Identify Dysplasia in Pathology Reports for Patients With Barrett's Esophagus. Clin Gastroenterol Hepatol. 2023 05; 21(5):1198-1204.
    View in: PubMed
    Score: 0.146
  57. Artificial intelligence in gastroenterology: A state-of-the-art review. World J Gastroenterol. 2021 Oct 28; 27(40):6794-6824.
    View in: PubMed
    Score: 0.138
  58. Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population. Clin Gastroenterol Hepatol. 2022 04; 20(4):e876-e889.
    View in: PubMed
    Score: 0.132
  59. Segment length and risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med. 2000 Nov 07; 133(9):747-8.
    View in: PubMed
    Score: 0.129
  60. Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients. Aliment Pharmacol Ther. 2020 07; 52(1):20-36.
    View in: PubMed
    Score: 0.125
  61. Barrett's esophagus, hiatal hernia, and logistic regression analysis. Am J Gastroenterol. 1999 Dec; 94(12):3395-6.
    View in: PubMed
    Score: 0.121
  62. Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma. Dig Dis Sci. 2019 02; 64(2):367-372.
    View in: PubMed
    Score: 0.112
  63. Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. Dig Dis Sci. 2018 11; 63(11):3112-3119.
    View in: PubMed
    Score: 0.110
  64. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther. 2018 08; 48(4):469-477.
    View in: PubMed
    Score: 0.109
  65. Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation. Clin Gastroenterol Hepatol. 2019 01; 17(1):65-72.e5.
    View in: PubMed
    Score: 0.109
  66. Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Am J Gastroenterol. 2018 08; 113(8):1148-1155.
    View in: PubMed
    Score: 0.109
  67. Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus. Eur J Cancer. 2017 04; 75:41-46.
    View in: PubMed
    Score: 0.099
  68. Risk Profiles for Barrett's Esophagus Differ between New and Prevalent, and Long- and Short-Segment Cases. PLoS One. 2016; 11(12):e0169250.
    View in: PubMed
    Score: 0.099
  69. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol. 2016 11; 111(11):1528-1535.
    View in: PubMed
    Score: 0.096
  70. Inverse Association Between Gluteofemoral Obesity and Risk of?Barrett's Esophagus in a Pooled Analysis. Clin Gastroenterol Hepatol. 2016 10; 14(10):1412-1419.e3.
    View in: PubMed
    Score: 0.095
  71. Weight Change and Weight Cycling Are?Not?Associated With Risk of Barrett's?Esophagus. Clin Gastroenterol Hepatol. 2016 12; 14(12):1839-1840.
    View in: PubMed
    Score: 0.095
  72. Coffee or Tea, Hot or Cold, Are Not Associated With Risk of Barrett's Esophagus. Clin Gastroenterol Hepatol. 2016 May; 14(5):769-72.
    View in: PubMed
    Score: 0.092
  73. Premature Birth and Large for Gestational Age Are Associated with Risk of Barrett's Esophagus in Adults. Dig Dis Sci. 2016 Apr; 61(4):1139-47.
    View in: PubMed
    Score: 0.091
  74. Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015 Nov; 149(6):1599-606.
    View in: PubMed
    Score: 0.090
  75. Physical activity and the risk of Barrett's esophagus. Dis Esophagus. 2016 Apr; 29(3):248-54.
    View in: PubMed
    Score: 0.087
  76. Esophageal carcinoma. N Engl J Med. 2014 Dec 25; 371(26):2499-509.
    View in: PubMed
    Score: 0.086
  77. Clinical and psychosocial variables associated with behavioral intentions to undergo surveillance endoscopy. BMC Gastroenterol. 2014 Jun 10; 14:107.
    View in: PubMed
    Score: 0.083
  78. Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. J Clin Gastroenterol. 2014 Mar; 48(3):218-23.
    View in: PubMed
    Score: 0.081
  79. Patient experiences with surveillance endoscopy: a qualitative study. Dig Dis Sci. 2014 Jul; 59(7):1378-85.
    View in: PubMed
    Score: 0.081
  80. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):229-238.e3.
    View in: PubMed
    Score: 0.078
  81. Patients' intuitive judgments about surveillance endoscopy in Barrett's esophagus: a review and application to models of decision-making. Dis Esophagus. 2013 Sep-Oct; 26(7):682-9.
    View in: PubMed
    Score: 0.075
  82. Esophageal eosinophilia after radiofrequency ablation for Barrett's esophagus. Dis Esophagus. 2013 Sep-Oct; 26(7):674-7.
    View in: PubMed
    Score: 0.075
  83. Patient-centered, comparative effectiveness of esophageal cancer screening: protocol for a comparative effectiveness research study to inform guidelines for evidence-based approach to screening and surveillance endoscopy. BMC Health Serv Res. 2012 Aug 28; 12:288.
    View in: PubMed
    Score: 0.073
  84. Barrett's esophagus: clinical features, obesity, and imaging. Ann N Y Acad Sci. 2011 Sep; 1232:36-52.
    View in: PubMed
    Score: 0.068
  85. Barrett's esophagus in children and adolescents without neurodevelopmental or tracheoesophageal abnormalities: a prospective study. Gastrointest Endosc. 2011 May; 73(5):875-80.
    View in: PubMed
    Score: 0.066
  86. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2009 Dec; 7(12):1299-304.
    View in: PubMed
    Score: 0.058
  87. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci. 2008 Sep; 53(9):2307-12.
    View in: PubMed
    Score: 0.055
  88. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008 Mar; 67(3):394-8.
    View in: PubMed
    Score: 0.052
  89. The association of body mass index with Barrett's oesophagus. Aliment Pharmacol Ther. 2005 Nov 15; 22(10):1005-10.
    View in: PubMed
    Score: 0.046
  90. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005 Aug 02; 143(3):199-211.
    View in: PubMed
    Score: 0.045
  91. Characteristics of intestinal metaplasia in the gastric cardia. Am J Gastroenterol. 1999 Mar; 94(3):622-7.
    View in: PubMed
    Score: 0.029
  92. Economic aspects of endoscopic screening for intestinal precancerous conditions. Gastrointest Endosc Clin N Am. 1997 Jan; 7(1):165-84.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.